# Dispatch Bio

> Dispatch Bio is a Philadelphia-based cancer biotech that emerged from stealth in July 2025 with $216 million to pursue a 'universal' immunotherapy for solid tumors. Its first-in-class Flare platform uses an engineered virus to install a synthetic, tumor-specific antigen on cancer cells while remodeling the tumor's immune-suppressive environment, effectively giving CAR T cells a target where none existed. Founded in 2022 out of the Parker Institute for Cancer Immunotherapy and ARCH Venture Partners, the company is led by CEO Sabah Oney and counts CAR T pioneer Carl June among its scientific co-founders.

- **Founded:** 2022
- **Headquarters:** Philadelphia, Pennsylvania, United States
- **Founders:** Sabah Oney (CEO (Co-Founder); previously venture partner at ARCH, exec at Alector and Ariosa Diagnostics), Carl June (Scientific Co-Founder; CAR T pioneer, University of Pennsylvania), Kole Roybal (Scientific Co-Founder; PICI Center Director, UCSF), K. Christopher Garcia (Scientific Co-Founder; Stanford University School of Medicine), Andy Minn (Scientific Co-Founder; immuno-oncology researcher), Lex Johnson (Co-Founder, Chief Platform Officer)
- **Team size:** ~65 employees
- **Products:** Flare Platform, DISP-10
- **Notable:** Raised $216 million and emerged from stealth in July 2025 backed by ARCH and the Parker Institute., Assembled scientific co-founders including CAR T pioneer Carl June, Kole Roybal, Chris Garcia and Andy Minn., Presented preclinical data supporting the Flare platform at SITC 2025, showing tumor-specific labeling and clearance with no activity in healthy cells.

## Products & services

- **Flare Platform** — First-in-class platform that delivers a tumor-targeted viral vector carrying a novel, synthetic 'universal' antigen (Flare). The virus tags solid tumor cells with the antigen while simultaneously breaking down the tumor's immune-suppressive microenvironment, so the immune system - including CAR T cells - can find and clear the cancer without harming healthy tissue.
- **DISP-10** — First clinical program: a tumor-targeted virus (DV-10) expressing a modified BCMA antigen (dBCMA), IL-18 and CXCL9, paired with BCMA-directed CAR T cells (Bristol Myers Squibb's ide-cel). Designed to treat epithelial-origin solid tumors. First-in-human Phase 1 planned for 2026.

## Achievements

- Raised $216 million and emerged from stealth in July 2025 backed by ARCH and the Parker Institute.
- Assembled scientific co-founders including CAR T pioneer Carl June, Kole Roybal, Chris Garcia and Andy Minn.
- Presented preclinical data supporting the Flare platform at SITC 2025, showing tumor-specific labeling and clearance with no activity in healthy cells.
- Advanced first clinical program DISP-10 toward a planned first-in-human Phase 1 in 2026.
- Recruited former Spark Therapeutics CEO Jeff Marrazzo as board chairman.

## Latest updates

- **2025-07** — Emerged from stealth with $216M and a plan for a universal solid-tumor immunotherapy built on the Flare platform.
- **2025-11** — Unveiled first clinical program DISP-10 and presented supporting Flare platform data at SITC 2025.
- **2026** — Plans to initiate a first-in-human Phase 1 study of DISP-10 across multiple solid tumor types.

## Links

- Website: https://dispatchbio.com
- LinkedIn: https://www.linkedin.com/company/dispatch-bio/
- Twitter/X: https://x.com/DispatchBio

---

Profile page: https://yespress.io/dispatch-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-12